WallStreetZenWallStreetZen

NASDAQ: AGLE
Aeglea Biotherapeutics Inc Stock

$11.86+0.19 (+1.63%)
Updated Sep 22, 2023
AGLE Price
$11.86
Fair Value Price
$21.21
Market Cap
$48.01M
52 Week Low
$2.66
52 Week High
$39.00
P/E
-0.17x
P/B
-0.23x
P/S
35.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.23M
Earnings
-$272.56M
Gross Margin
100%
Operating Margin
-22,211.64%
Profit Margin
-22,195.4%
Debt to Equity
-1.22
Operating Cash Flow
-$67M
Beta
1.18
Next Earnings
Nov 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A

AGLE Overview

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Zen Score

Industry Average (24)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AGLE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AGLE ($11.86) is undervalued by 44.08% relative to our estimate of its Fair Value price of $21.21 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AGLE ($11.86) is significantly undervalued by 44.08% relative to our estimate of its Fair Value price of $21.21 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AGLE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AGLE due diligence checks available for Premium users.

Be the first to know about important AGLE news, forecast changes, insider trades & much more!

AGLE News

Valuation

AGLE fair value

Fair Value of AGLE stock based on Discounted Cash Flow (DCF)
Price
$11.86
Fair Value
$21.21
Undervalued by
44.08%
AGLE ($11.86) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AGLE ($11.86) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AGLE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AGLE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.17x
Industry
12.89x
Market
14.52x

AGLE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.23x
Industry
5.11x

AGLE's financial health

Profit margin

Revenue
$688.0k
Net Income
-$217.1M
Profit Margin
-31,552.5%
AGLE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AGLE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$243.5M
Liabilities
$253.6M
Debt to equity
-1.22
AGLE's short-term assets ($239.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AGLE's short-term assets ($239.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AGLE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AGLE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$16.6M
Investing
$6.8M
Financing
$210.0M
AGLE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AGLE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AGLE$48.01M+1.63%-0.17x-0.23x
VANI$48.28M+1.06%-2.44x1.49x
ASMB$48.62M-1.70%-0.57x0.88x
VTGN$49.15M+1.94%-0.81x7.18x
IPA$49.35M-4.83%-3.21x1.26x

Aeglea Biotherapeutics Stock FAQ

What is Aeglea Biotherapeutics's quote symbol?

(NASDAQ: AGLE) Aeglea Biotherapeutics trades on the NASDAQ under the ticker symbol AGLE. Aeglea Biotherapeutics stock quotes can also be displayed as NASDAQ: AGLE.

If you're new to stock investing, here's how to buy Aeglea Biotherapeutics stock.

What is the 52 week high and low for Aeglea Biotherapeutics (NASDAQ: AGLE)?

(NASDAQ: AGLE) Aeglea Biotherapeutics's 52-week high was $39.00, and its 52-week low was $2.66. It is currently -69.59% from its 52-week high and 345.86% from its 52-week low.

How much is Aeglea Biotherapeutics stock worth today?

(NASDAQ: AGLE) Aeglea Biotherapeutics currently has 4,047,717 outstanding shares. With Aeglea Biotherapeutics stock trading at $11.86 per share, the total value of Aeglea Biotherapeutics stock (market capitalization) is $48.01M.

Aeglea Biotherapeutics stock was originally listed at a price of $244.25 in Apr 7, 2016. If you had invested in Aeglea Biotherapeutics stock at $244.25, your return over the last 7 years would have been -95.14%, for an annualized return of -35.09% (not including any dividends or dividend reinvestments).

How much is Aeglea Biotherapeutics's stock price per share?

(NASDAQ: AGLE) Aeglea Biotherapeutics stock price per share is $11.86 today (as of Sep 22, 2023).

What is Aeglea Biotherapeutics's Market Cap?

(NASDAQ: AGLE) Aeglea Biotherapeutics's market cap is $48.01M, as of Sep 25, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aeglea Biotherapeutics's market cap is calculated by multiplying AGLE's current stock price of $11.86 by AGLE's total outstanding shares of 4,047,717.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.